NCT04644770 2026-04-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
22 trialsNCT05079698 2026-04-07
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04925583 2026-04-02
MAGELLAN
University Hospital Heidelberg
Phase 1 Active not recruiting
NCT06141031 2026-03-17
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT03223155 2026-03-04
COSINR
University of Chicago
Phase 1 Active not recruiting
NCT04943536 2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1 Active not recruiting
NCT04073745 2026-02-04
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT03824327 2026-01-28
Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02989636 2026-01-06
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT01923506 2025-11-26
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06132945 2025-11-14
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04926948 2025-10-22
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
Mayo Clinic
Phase 1 Active not recruiting
NCT01655836 2025-09-11
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03961971 2025-09-10
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05821231 2025-07-31
MEDISARC-SBRT
Institut Claudius Regaud
Phase 1 Active not recruiting
NCT05341349 2025-07-30
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Active not recruiting
NCT01843413 2025-07-20
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02685332 2025-07-20
Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
University of Texas Southwestern Medical Center
Phase 1 Active not recruiting
NCT02474368 2025-07-10
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02608385 2025-06-08
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
Phase 1 Active not recruiting
NCT05678010 2025-05-18
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04576091 2024-12-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting